Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
TipRanksApr 9 10:30
MannKind Analyst Ratings
BenzingaMar 15 22:50
MannKind's Strong Q4 Financials and Therapeutic Portfolio Potential Merit a Buy Rating
TipRanksMar 1 14:06
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target
BenzingaFeb 29 00:22
MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating
TipRanksFeb 28 21:55
MannKind (MNKD) Receives a New Rating From Cantor Fitzgerald
TipRanksFeb 28 21:35
RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)
TipRanksFeb 28 20:19
MannKind (MNKD) Receives a Hold From RBC Capital
TipRanksJan 6 09:47
Strategic Deal Boosts MannKind's Financial Prospects: A Buy Rating Justified
TipRanksJan 5 12:56
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $7.5 Price Target
BenzingaJan 4 19:29
MannKind Analyst Ratings
BenzingaJan 4 19:28
MannKind Buy Rating Affirmed: Financial Strength and Market Potential Underpin Positive Outlook
TipRanksJan 4 19:16
Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)
TipRanksDec 21, 2023 20:35
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating
MT NewswiresNov 14, 2023 21:21
Strong Q3 Results and Promising Clinical Progress: A Buy Rating for MannKind
TipRanksNov 10, 2023 19:31
Promising Growth and Expansion Potential Elevates MannKind to a Buy Rating
TipRanksNov 9, 2023 11:36
RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)
TipRanksNov 9, 2023 09:48
Analysts' Top Healthcare Picks: MannKind (MNKD), Stoke Therapeutics (STOK)
TipRanksNov 8, 2023 19:30
Wedbush Initiates Coverage On MannKind With Outperform Rating, Announces Price Target of $10
BenzingaOct 10, 2023 17:13
MannKind Analyst Ratings
BenzingaOct 10, 2023 17:12
No Data
No Data